Provider review
Eviora MD review: twenty-eight screens, your home address, and still no price
Eviora MD publishes one number: "from $149/mo". Its own copy hedges it — plans are confirmed after a provider reviews you. So we went through the whole signup to find the real one. Twenty-eight screens. Name, email, phone, date of birth, full shipping address. Not one dollar figure anywhere along the way. What does appear, on the very last screen, is a chart promising 18% of your body weight gone by week 24 — a number that beats the landmark trial in a third of the time, and that no one can see until they've handed over everything.
Asks for your date of birth and home address across twenty-eight screens without showing a price, then promises 18% by week 24.
Worth trusting if
- You want the plain statement that compounded medicines are not FDA-approved, which this site does give
- You are comparing the same template across brands and want to know it is the same product underneath
Be skeptical if
- You want to know what it costs before handing over your address, because the signup never tells you
- You are planning around the 18%-by-week-24 chart, which no published trial supports
- You want to know which company you are contracting with, or which pharmacy fills the prescription
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens evioramd.com. A link is not a recommendation to take anything.
Provenance
What Eviora MD actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded semaglutide injection
- Compounded tirzepatide injection
- GLP-1 Microdose
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
2
Molecules with human evidence
For the use they are sold for, out of 3 products reviewed here. The evidence belongs to the molecule, not to Eviora MD.
3
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Eviora MD’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
Compounded semaglutide injectionSemaglutide · Compounded (503A)Claim reaches past the trials
“WHAT GLP-1 CARE CAN DO. A steady path to real, lasting results. TYPICAL GLP-1 PROGRESS −18% body weight. WEEK 0 · WEEK 12 · WEEK 24. In clinical trials, provider-supervised GLP-1 therapy produced consistent weight loss over time.”
Read on the Eviora MD site, September 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. 68 weeks in 1,961 adults, titrated to semaglutide 2.4 mg. Reported a mean weight reduction of about 15% — at 68 weeks, not at 24.
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg tirzepatide. Its roughly 20% mean is the highest published for an approved medicine in this class, and it took 72 weeks.
The chart puts 18% of body weight gone at week 24, and calls it typical. STEP 1 reported about 15% after 68 weeks on semaglutide, so this promises more than the landmark trial delivered in roughly a third of the time. Even SURMOUNT-1's tirzepatide result, the highest published for an approved medicine in this class, needed 72 weeks to reach about 20%. Eviora MD's own footnote calls the chart illustrative of published trial averages, which is where it comes apart: no published average looks like this. Two things make it worse rather than better. The chart is not on any public page — it appears only on the final screen of a signup, after a reader has given their name, email, phone, date of birth and home address. And the same screen still shows no price.1,2
Compounded tirzepatide injectionTirzepatide · Compounded (503A)Claim matches the trials
“Tirzepatide — Advanced Weight Loss. Modern, provider-guided GLP-1 care for weight, metabolic health, and longevity — personalized plans that meet you where you are and evolve as your goals do.”
Read on the Eviora MD site, September 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. 72 weeks in 2,539 adults at 5, 10 and 15 mg once weekly, mean reduction of roughly 20% at the top dose.
The public tirzepatide page makes no outcome claim at all — it describes the program and promises nothing measurable, so there is nothing on it to weigh against SURMOUNT-1. That restraint does not survive the signup, though: the same 18%-by-week-24 chart appears at the end of the tirzepatide route as it does at the end of the semaglutide one, with no distinction drawn between the two molecules. A reader who picks tirzepatide sees the same promise as a reader who picks semaglutide, and the trials for the two are not the same.2
GLP-1 MicrodoseGLP-1 (molecule not named) · Compounded (503A)No trial supports this claim
“GLP-1 Microdose — Longevity & Composition. Lower-dose, steady results.”
Read on the Eviora MD site, September 2026
No trial for this use
No trial can be matched to this product because Eviora MD never says what is in it. Searched on September 13, 2026 across every page of its own site — the homepage, all three treatment pages, the terms and the privacy notice — plus all twenty-eight screens of the signup: no molecule and no dose is named for the microdose product anywhere. A trial record cannot be attached to an unnamed drug, and guessing which one it is would be inventing the evidence base.
"Lower-dose, steady results" names a direction and a drug class, and no drug. Even if the molecule were named, microdosing is not what either trial studied: STEP 1 and SURMOUNT-1 both titrated participants up to a maintenance dose and measured them there, so a deliberately reduced dose sits outside the published evidence rather than inheriting it. With the compound unnamed there is nothing at all to weigh the claim against.
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named. The footer describes the arrangement as a category — the platform facilitates access to independent, US-licensed clinical providers and state-licensed compounding pharmacies — and names neither the doctors nor the pharmacy, at any point on their site or across the signup. Nothing says whether your medication is made to order under a prescription or dispensed ready-made. What the same disclaimer does say, plainly, is that compounded medications are not FDA-approved and that their safety, efficacy and quality have not been independently verified by the FDA. That sentence is better than much of this market manages, and it sits on every page.
Read on the Eviora MD site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
No certificate of analysis, potency, purity or sterility result appears anywhere on the site or in the signup. The trust signals are social and undated — "10k+ Trusted by thousands of members", an average care rating shown as a bare figure, before-and-after photographs marked "individual results vary", and a testimonial screen inserted partway through the signup quoting a specific weight loss. The one quantified clinical claim on the whole property is the 18%-by-week-24 chart, and it is visible only to people who have already completed the intake.
Read on the Eviora MD site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
Eviora MD says telehealth nationwide on its treatment pages and publishes no list of states, no exclusions and no fifty-state claim, checked on September 13, 2026 across the homepage, the three treatment pages, the terms and the full signup. The signup never asks which state you are in — it asks for a full shipping address instead, at screen twenty-five.
Read the full licensing claim
No company is named on any page. The footer is a copyright line, and the terms and privacy pages give no business name, address or state. The browser tab carries the string "EVIORA LLC" and nothing on the site repeats it, so we treat it as a page title rather than a verified legal name. No clinician is named anywhere.
Read on the Eviora MD site, September 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with Eviora MD
We went through Eviora MD’s signup ourselves in September 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- What would you like support with — long term health, feeling better day to day, confidence, or reducing health risks
- How active are you usually
- How much sleep do you normally get
- How often are you stressed
- What is your gender
- Height, current weight and goal weight
- A BMI analysis screen, showing a score, an "elevated" label and a "success outlook" of 92%
- First name and last name
- Email address
- Phone number
- Which best describes your body shape
- What is your ethnicity
- A symptom checklist — low libido, skin problems, brain fog
- A diagnosis checklist — thyroid cancer, family history, endocrine neoplasia, active cancer
- Have you had any surgeries or procedures
- Have you had any weight-loss surgeries
- A testimonial screen — a before-and-after photograph and "Down 38 lbs"
- Have you ever taken a GLP-1 medication
- Do you take any medications or supplements
- Are you allergic to any of these
- Any other medication or food allergies
- What is your resting heart rate
- How disruptive would side effects be to your routine
- Your date of birth
- Your full shipping address
- A final consent screen, with a chart promising 18% of body weight lost by week 24
- No price appears at any point in the signup — not on one of the twenty-eight screens we cleared on September 13, 2026.
- The only figure published anywhere on the site is "from $149/mo", and Eviora MD's own wording qualifies it as confirmed after a provider reviews you.
- Your email address is asked for at screen nine, before any clinical question about medication, allergies or diagnosis.
- Your date of birth and full shipping address are asked for before any price is shown.
- A "success outlook" of 92% is displayed on the BMI screen, and a "success probability" of 92% on the medical-review screen, both before a clinician has seen anything.
- The 18%-by-week-24 chart appears only on the final screen, so nobody comparing providers from the outside can see it.
- The final screen requires confirming that your answers are true, accurate and complete before the qualification button unlocks — which is where we stopped, because ours were not.
Eviora MD support
- info@evioramd.com
Assessment
What holds up, and what does not
- Its disclaimer says plainly that compounded medications are not FDA-approved and have not been verified by the FDA.
- The final screen's chart carries a hedge — illustrative, individual results vary, not guaranteed.
- Its contraindication screen asks specifically about thyroid cancer, family history and endocrine neoplasia.
Show 3 more
- The signup asks a real medical history — medications, allergies, surgeries, resting heart rate.
- Its public treatment pages make no outcome claim at all.
- No FDA warning letter.
- No price appears on any of the twenty-eight signup screens we cleared, or anywhere else on the site.
- It asks for your date of birth and full shipping address before showing you a number.
- Your email is collected at screen nine, before a single question about medication or diagnosis.
Show 8 more
- Its chart promises 18% of body weight lost by week 24, which beats the landmark trial in a third of the time.
- That chart is visible only after the intake, so nobody comparing providers from outside can see it.
- A "success outlook" of 92% is shown on a BMI screen before any clinician has looked at anything.
- The same 92% reappears as a "success probability" on the screen headed medical review.
- The same 18% chart ends both the semaglutide and the tirzepatide routes, though the trials differ.
- Its microdose product names no molecule and no dose anywhere on the site.
- No company is named — the terms and privacy pages give no business name, address or state.
- No pharmacy and no clinician is named at any point.
Verdict
The bottom line
Do not start this signup expecting to learn the price. We gave it a name, an email, a phone number, a date of birth and a home address across twenty-eight screens and it never quoted a figure. If you do reach the end, the chart waiting there promises more weight loss by week 24 than the landmark trial produced in 68 weeks — treat that as advertising, because that is what it is.
Opens evioramd.com. A link is not a recommendation to take anything.
We went all the way through
Eviora MD publishes exactly one number anywhere on its site:
"GLP-1 weight loss programs from $149/mo"
And qualifies it itself: "Plans from $149/mo · confirmed after provider review."
So on 13 September 2026 we completed the signup to find the real one. Twenty-eight screens. Goals, activity, sleep, stress, sex, height, weight, goal weight, a BMI analysis, first and last name, email, phone, body shape, ethnicity, symptoms, diagnoses, surgeries, weight-loss surgeries, a testimonial interstitial, GLP-1 history, medications, allergies, more allergies, resting heart rate, side-effect tolerance, date of birth, and a full shipping address.
Not one dollar figure. At any step.
Full analysis — 4 more sectionsWhat is waiting at the end · Where that chart lives · Where we stopped, and why · The same site, twice more
What is waiting at the end
The final screen, headed "WHAT GLP-1 CARE CAN DO":
TYPICAL GLP-1 PROGRESS
−18% body weight
WEEK 0 · WEEK 12 · WEEK 24
STEP 1 randomized 1,961 adults and reported a mean reduction of about 15% — after 68 weeks. 1
SURMOUNT-1's tirzepatide result, the highest published for an approved medicine in this class, reached roughly 20% — after 72 weeks. 2
Eviora MD's chart promises 18% by week 24. That is more than the landmark semaglutide trial delivered, in roughly a third of the time.
Its own footnote says the chart is "illustrative of published trial averages". That is exactly the problem: no published average looks like this.
Where that chart lives
Not on the homepage. Not on the treatment pages. Nowhere anyone comparing providers can see it.
It appears on screen twenty-eight, after a reader has handed over their name, email, phone, date of birth and home address. The one quantified clinical promise on the whole property is visible only to people who have already given up everything needed to contact them.
Two earlier screens do something similar and quieter. The BMI screen shows "Your success outlook 92%". The screen headed "Your Medical Review" shows "Success Probability 92%" and "You could reach your goal weight in about 31 weeks."
No clinician has seen anything at that point. It's a quiz.
Where we stopped, and why
The last screen requires ticking:
"I confirm my answers are true, accurate, and complete…"
Ours were not — every one was invented for this walk. Ticking that box would be an affirmative false statement to a healthcare provider, which is a different act from filling in a public form, so we stopped there.
We did not need it. The finding was already complete: you can give this company your home address and still not know what it charges.
The same site, twice more
rxbella.com and mynewwavehealth.com run the identical template — same page addresses, same footer disclaimer bar the brand name, and, we confirmed on the same day, the same twenty-eight screens and the same 18%-by-week-24 panel, word for word.
None of the three names a company, so there is no way to establish a relationship between them or rule one out. White-labeled telehealth platforms are ordinary and several unrelated brands running one is the normal explanation. It matters for one practical reason: if you are comparing two of them, you may be comparing the same thing twice.
Questions
Frequently asked questions
What does Eviora MD actually cost?
We don't know, and neither will you before you sign up. The site publishes "from $149/mo" and says plans are confirmed after a provider reviews you. We completed twenty-eight signup screens on September 13, 2026 — including date of birth and full shipping address — and were shown no figure at any point.
Is 18% of body weight by week 24 realistic?
Not on the published record. STEP 1 reported about 15% after 68 weeks of semaglutide, and SURMOUNT-1's tirzepatide result reached roughly 20% after 72 weeks. A chart promising 18% at week 24 is claiming more than the landmark trial achieved in about a third of the time.
Where is that chart?
On the last screen of the signup, and nowhere else. It isn't on the homepage or any treatment page, so nobody comparing providers from the outside can see it. By the time it appears you've already given your name, email, phone, date of birth and home address.
What is the 92% success probability?
A number the site generates from your height, weight and goal weight, shown on two screens before any clinician has looked at anything. No trial reports a success probability for an individual — the published results are averages with a spread around them, including people who did not respond.
Is this the same company as RX Bella or New Wave Health?
Nobody can tell, including us. All three use the same template — the same page addresses, the same twenty-eight signup screens, the same disclaimer differing only in the brand name — and none of the three names a company. It matters only in that comparing two of them may mean comparing the same thing twice.
Glossary
Key terms
Show definitions
- STEP 1
- The phase 3 trial of once-weekly semaglutide 2.4 mg for weight loss — 1,961 adults over 68 weeks, published in the New England Journal of Medicine in 2021. Its roughly 15% mean is the figure most semaglutide marketing traces back to.
- SURMOUNT-1
- The phase 3 trial of once-weekly tirzepatide for weight loss — 2,539 adults over 72 weeks at 5, 10 and 15 mg, published in the New England Journal of Medicine in 2022.
- Compounded
- Made to order by a pharmacy for an individual patient rather than manufactured and approved as a finished product. Compounded drugs are not FDA-approved and the FDA has not evaluated their safety, effectiveness or quality.
Compare
Others selling what Eviora MD sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked September 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Eviora MD's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 2 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — 1,961 adults, mean weight reduction of about 15% reported at 68 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT03548935
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — 2,539 adults, roughly 20% mean reduction at the top dose reported at 72 weeks. New England Journal of Medicine. https://clinicaltrials.gov/study/NCT04184622
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.